Ipamorelin / CJC-1295 mix 5 mg + 5 mg

Ipamorelin / CJC-1295 Blend 10 mg (5 mg + 5 mg) research-grade lyophilized peptide powder in a glass vial. This blend combines the selective ghrelin receptor agonist Ipamorelin with CJC-1295 (no DAC, Mod GRF 1-29), a Growth Hormone Releasing Hormone (GHRH) analog, studied in experimental models of pituitary function and growth hormone (GH) secretion dynamics.

Research Overview

The Ipamorelin / CJC-1295 (no DAC) Blend 10 mg (5 mg + 5 mg) combines two complementary growth hormone secretagogues: Ipamorelin, a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R), and CJC-1295 (no DAC), a modified GHRH analog (Mod GRF 1-29). In experimental endocrinology, this dual-agonist blend is used as a tool compound to investigate GH/IGF-1 axis regulation, pituitary signaling and pulsatile growth hormone secretion patterns in in vitro and in vivo research models.

Primary Research Areas

• Growth hormone secretion dynamics: Laboratory models exploring synergistic GH release via concurrent activation of GHS-R by Ipamorelin and GHRH receptors by CJC-1295 (no DAC), including studies of GH pulse amplitude and frequency [1,2].
• Pituitary and hypothalamic signaling: Experiments evaluating downstream intracellular pathways in pituitary somatotrophs and hypothalamic circuits in response to combined ghrelin receptor and GHRH receptor stimulation [1].
• GH/IGF-1 axis modulation: Preclinical research assessing how the blend influences growth hormone and insulin-like growth factor 1 (IGF-1) patterns in controlled endocrine models, without implying any therapeutic or performance outcomes [2].
• Endocrine feedback and receptor interactions: Studies focused on feedback regulation, receptor desensitization and cross-talk between ghrelin, GHRH and somatostatin pathways under dual-secretagogue stimulation [1].
• Method development and assay calibration: Use of the Ipamorelin / CJC-1295 blend as a reference tool in assay development, bioanalytical method validation and mechanistic GH secretion research in vitro and in vivo.
• More body fat in mice (Ipamorelin): twice-daily injections raised body weight about 15% within two weeks in mice and increased fat-pad weight relative to body weight, in growth-hormone-deficient and normal animals alike, with more food eaten. Growth hormone itself did the opposite. In mice the fat arrived without growth hormone being responsible [3].
• Bones grew wider, not denser (Ipamorelin): female rats on 0.5 mg/kg a day for 12 weeks gained bone mineral content, but once their extra body weight was allowed for the density was unchanged: the bones had simply grown larger. Bigger is not the same as stronger, and this has never been measured in people [4].
• Steroid muscle loss (Ipamorelin): rats on three months of methylprednisolone lost calf-muscle force and bone formation; 100 µg/kg three times a day restored maximum calf tension and raised new bone at the periosteum four-fold against the steroid alone. Rats on a heavy steroid dose, which is not a person on prednisolone [5].
• A failed bowel trial (Ipamorelin): 114 patients recovering from bowel surgery were given ipamorelin or placebo twice daily for up to a week; the first tolerated meal came at 25.3 hours against 32.6, which was not significant, and no secondary measure differed. It was well tolerated. This is the only efficacy trial in people [6].
• Deep sleep (CJC-1295’s parent hormone): seven men were given four 50 µg boluses of natural GHRH across the late evening; deep slow-wave sleep rose from 14% to 20% of the night, growth hormone tripled and overnight cortisol fell. CJC-1295 without DAC is a GHRH copy, but was not the molecule tested [7].
• Weight loss during chemotherapy (Ipamorelin): ferrets given cisplatin ate less and lost weight; ipamorelin at 1 to 3 mg/kg did nothing for the vomiting but cut the later weight loss by roughly 24%. Small animals and one chemotherapy drug, and the appetite effect behind it is what put fat on mice [8].

References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822. doi:10.1530/eje.0.1390552
2. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. doi:10.1210/jc.2005-1536
3. Lall S, Tung LY, Ohlsson C, et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-8. PMID 11162489. doi:10.1006/bbrc.2000.4065
4. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-77. PMID 10828840. doi:10.1677/joe.0.1650569
5. Andersen NB, Malmlöf K, Johansen PB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-72. PMID 11735244. doi:10.1054/ghir.2001.0239
6. Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PMID 25331030. doi:10.1007/s00384-014-2030-8
7. Steiger A, Guldner J, Hemmeter U, et al. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology. 1992;56(4):566-73. PMID 1361964. doi:10.1159/000126275
8. Lu Z, Ngan MP, Liu JYH, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiol Behav. 2024;284:114644. PMID 39043357. doi:10.1016/j.physbeh.2024.114644